Are Peptides Legal in the US? What Depends on the Product

Peptides are not banned as a class in the United States, and they are not freely available either. Legality depends on what the product is, how it is made, who sells it and for what use. FDA-approved peptide medicines are legal with a prescription, cosmetic peptides in skincare are legal to sell as cosmetics, and unapproved peptides sold as “research chemicals” are not legal to sell for human use, according to Drugs.com’s overview of peptides and their legal status. Compounded peptides sit in the middle, and their position changed in late 2026.
This guide explains each category, what changed in 2026, and how to tell a licensed prescription pathway from a gray-market product.
VivoChoose a supervised peptide pathwayVivo offers provider-supervised treatments, with precision-compounded therapies prepared by licensed U.S. pharmacies and delivered to your door.VisitTL;DR
- FDA-approved peptide drugs such as semaglutide and tirzepatide are legal with a prescription from a licensed provider.
- Research-use-only peptides are not legal to sell for human use, and the “research” label does not change that.
- Compounded peptides depend on the specific peptide, the compounding pharmacy and a prescription written for an individual patient. A draft HHS policy published on October 30, 2026 is temporary and can be withdrawn.
- State boards can be stricter than federal policy, so your state matters.
- A legitimate pathway has a named licensed prescriber, a licensed U.S. pharmacy and a prescription tied to you.
Table of Contents
- The short answer: four legal categories
- FDA-approved peptides: the clearest legal ground
- Cosmetic peptides
- Research-use-only peptides: not legal for human use
- Compounded peptides: what changed in 2023 and 2026
- Is BPC-157 going to be approved?
- Do bans apply to athletes?
- How to tell a legitimate prescription pathway from a gray-market one
- Perspective
- Prescription options through Vivo
- FAQ
- Sources
The short answer: four legal categories
Most confusion comes from the word “peptide” covering very different products. A peptide is a short chain of amino acids, the building blocks of proteins. Insulin is a peptide. So is the active ingredient in a skin serum. The law treats them according to how they are sold, not what they are called.
| Category | Examples | Legal status |
|---|---|---|
| FDA-approved peptide medicines | Semaglutide (Wegovy), tirzepatide (Zepbound), liraglutide (Saxenda), setmelanotide (Imcivree), insulin | Legal with a prescription |
| Cosmetic peptides | Peptides in skincare products | Legal to sell as cosmetics |
| Compounded peptides | Prescription preparations made by a pharmacy for one patient | Depends on the peptide and the pharmacy; the position shifted in 2026 |
| Research-use-only peptides | BPC-157 and TB-500 sold online as lab products | Not legal to sell for human use |
The approved weight-loss peptides are listed in Drugs.com’s review of FDA-approved peptides for weight loss, which notes that retatrutide, AOD-9604 and MOTS-c are not FDA-approved.
FDA-approved peptides: the clearest legal ground
When a peptide has gone through FDA review, the question is simple. A licensed provider can prescribe it, and a pharmacy can dispense it. The same Drugs.com source identifies semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) among them, alongside insulin.
Approval is specific to a use. Drugs.com’s weight-loss review notes that tesamorelin (Egrifta WR) is approved to reduce excess belly fat in adults with HIV lipodystrophy, not for general weight loss. A drug can be legal and approved and still be appropriate only for certain patients, which is why a provider’s review comes first.
For readers considering GLP-1 medicines, our guides on compounded semaglutide safety and compounded tirzepatide safety cover what to verify before use.

Cosmetic peptides
Peptides in skincare are sold as cosmetics, which is a separate legal category from drugs. Products in this category are legal to sell as long as they are marketed as cosmetics and do not make drug claims. Prescription topical products are different: they are prepared for an individual patient after a provider’s review, not sold over the counter.
Research-use-only peptides: not legal for human use
This is the category that causes the most legal and safety trouble. Websites sell vials of BPC-157, TB-500 and similar peptides labeled “for research purposes only.” Drugs.com states that the research-use-only label does not make a product safe or legal, and that FDA has sent warning letters to sellers whose websites described human uses.
The label also has no standing with medical regulators. The Alabama Board of Medical Examiners states in an official notice that research-grade peptides have not been tested or determined safe or effective for human use, and that their contents cannot be verified. The Board says no physician may compound, administer or dispense them, and that this extends to nurse midwives, nurse practitioners and physician assistants.
Mississippi’s medical licensure, nursing and pharmacy boards reached the same position in a joint statement. It adds that a patient consent form calling a product “research-grade” does not remove a provider’s professional or legal liability. If a person acquires and self-administers such a substance independently, the statement says the risk rests with that person.
For buyers who have been ordering research peptides, the practical point is this: a vial with no verified contents, no prescriber and no pharmacy record offers none of the protections a prescription pathway provides.
Compounded peptides: what changed in 2023 and 2026
Compounding is when a licensed pharmacy prepares a medication for an individual patient based on a prescription. Federal law, under section 503A of the Federal Food, Drug, and Cosmetic Act, sets conditions for this, including which bulk ingredients a pharmacy may use. A compounded drug is not FDA-approved, so, as the Federal Register notice states, FDA does not review its safety, effectiveness or quality before it is marketed. That is why pharmacy licensing, prescriber oversight and ingredient sourcing carry so much weight.
2023: the Category 2 list
In late 2023, FDA flagged 19 popular peptides, including BPC-157 and TB-500, as Category 2 bulk drug substances presenting significant safety concerns. ArentFox Schiff’s legal analysis explains this effectively barred them from traditional compounding, while a gray market of research-use-only sellers kept operating behind disclaimers that FDA does not recognize.
2026: advisory votes and an interim policy
In July 2026, an FDA advisory committee voted to recommend allowing six peptides: BPC-157, TB-500, KPV, MOTS-c, Semax and epitalon. Drugs.com reports that FDA scientists had advised against all of them and that the committee voted against a seventh, emideltide. Per Holland & Knight’s October 2026 briefing, those votes were recommendations only, and no peptide had been added to the 503A Bulks List.
On October 30, 2026, HHS published a draft enforcement-discretion policy in the Federal Register for 503A compounding with certain peptide bulk substances while the formal bulks list is developed through rulemaking. The notice states the policy is a draft, does not establish rights for any person and is not binding on HHS or the public. HHS may revisit it if a safety signal or product quality issue arises.

What the interim policy requires
According to Morgan Lewis, the prerequisites are:
- Only BPC-157, Epitalon, KPV, MOTS-c, Semax or TB-500 may be compounded.
- Products may contain a single peptide and no other active pharmaceutical ingredients.
- Identity and route-of-administration requirements must be met.
- The peptide must be produced at a cGMP-compliant, FDA-registered drug establishment.
Drugs.com adds that the conditions include a valid prescription for an individual patient, a certificate of analysis from an FDA-registered manufacturer, certain forms per peptide (Semax only as a nasal product, for example), a label stating the product is a compounded drug not for resale, and reporting of serious side effects to FDA. It notes the policy does not cover CJC-1295, ipamorelin or injectable GHK-Cu.
What it does not do
Enforcement discretion is not approval. Morgan Lewis attorneys caution that it is not a legal shield, does not change the underlying statutory requirements, and can be modified later by HHS or FDA. Holland & Knight states it would not cover research-use-only, supplement or 503B outsourcing facility channels, could be withdrawn without formal rulemaking, and that a lasting federal pathway is expected to be a 2027 to 2028 development. The same briefing reports that FDA stepped up enforcement against research-use-only sellers and high-volume compounders from August 2026.
The policy is also not the last word on legality. Morgan Lewis notes that state medical and pharmacy boards regulate compounding pharmacies and practitioners, and their requirements may differ from the federal policy in meaningful ways. State attorneys general have also discussed using consumer protection laws against peptide products sold on inaccurate or inadequately supported claims.
Is BPC-157 going to be approved?
Approval is a different process from compounding permission. Public Citizen’s July 2026 testimony to FDA argues BPC-157 should go through the standard new-drug approval process, and says no new clinical evidence since 2023 has shown it is effective or safe. As of this writing it is not FDA-approved. Drugs.com makes the same point for BPC-157 and TB-500: little evidence on safety or effectiveness in people.
Do bans apply to athletes?
Yes, in organized sport. USADA’s 2026 Clean Sport Handbook lists peptide hormones such as growth hormone, growth hormone releasing peptides (GHRPs) and related substances and mimetics as non-specified prohibited substances on the WADA Prohibited List. The default sanction for a first violation is four years of ineligibility. This applies to athletes subject to anti-doping testing, not to general clinical or recreational use. If you compete in a tested event, confirm any prescription with the anti-doping organization before starting it. Most gym members, yoga and Pilates practitioners and instructors are not subject to this testing.
How to tell a legitimate prescription pathway from a gray-market one
When the law is in motion, process matters more than a product name. Five questions separate a licensed pathway from a risky one:
- Is a named licensed provider reviewing your health history? A prescription must be written for you as an individual patient. Our piece on who prescribes peptides in the U.S. explains how your location sets the rules.
- Which pharmacy prepares it? It should be a licensed U.S. pharmacy, and you should be able to learn which one. Our checklist on compounding pharmacy safety covers what patients should verify.
- Is the product FDA-approved, or compounded under a recognized pathway? Anything labeled only “research use” fails this test.
- Is the intake private? Health information collected by a telehealth service should be handled under HIPAA, the federal health privacy law.
- Is there ongoing oversight? Screening, side-effect monitoring and refill review belong to the prescriber. See our overview of peptide therapy safety, risks and screening.
Perspective
Readers ask us whether a peptide is “legal” as if it were a yes or no question. It is a question about the pathway. The same molecule can be a legitimate prescription in one channel and an unlawful sale in another.
Our position is that the pathway is what protects a patient: a licensed provider who reviews your history, a licensed U.S. pharmacy that prepares the therapy, and ongoing supervision after it ships. That is how we build our service, and it is why our therapies are prescription-compounded by licensed U.S. pharmacies and delivered to the patient’s door.
The 2026 federal changes concern a small group of peptides, such as BPC-157 and TB-500, that are not part of our offering. For the therapies we do offer, we focus on personalized, guided treatment selection, medical supervision and HIPAA-compliant data practices. A patient who has been buying research-use-only vials is better served by a prescription tied to a named provider and pharmacy than by a vial with unverified contents.
Jack
Prescription options through Vivo
Our therapies are provider-supervised and prescription-compounded by licensed U.S. pharmacies, with telehealth intake, treatment selection and ongoing provider oversight, so no in-person visit is needed. Plans published on our site as of November 2026 include:
- NAD+ Nasal Spray: $119 per month
- Glutathione Nasal Spray: $149 per month
- Sermorelin: $135 per month
- MIC+B12: $109 per month
- Semaglutide: $199 per month
If you are comparing options, we also explain prescription NAD+ against NMN and NR supplements. Treatment is approved only after provider review, and decisions are individualized. For wider cost context, see our peptide therapy cost guide.
FAQ
Are peptides legal in the US?
Many are. FDA-approved peptide medicines are legal with a prescription, and cosmetic peptides are legal to sell as cosmetics. Peptides sold as research chemicals for human use are not legal to sell. Compounded peptides depend on the specific peptide, the pharmacy and a prescription for an individual patient.
Which peptides are legal in the United States?
Approved examples include insulin, semaglutide, tirzepatide, liraglutide and setmelanotide, each with an FDA-approved indication. Peptides such as BPC-157 and TB-500 are not FDA-approved. Under the October 2026 draft HHS policy, a short list may be compounded under specific conditions, and that policy can change.
Are peptides on the banned substance list?
For tested athletes, yes. USADA’s 2026 handbook lists growth hormone, growth hormone releasing peptides and related substances as prohibited under the WADA list. The ban applies to people subject to anti-doping testing, not to general clinical use.
Will peptides become legal in the US?
Some access is already moving through an interim policy, but it is temporary. A lasting federal pathway is expected to be a 2027 to 2028 development, according to Holland & Knight. Check the FDA and your state board for the current position before starting anything.
Sources
- Peptides: what they are, uses, safety and legal status (Drugs.com)
- Peptides for weight loss: which are FDA-approved (Drugs.com)
- Federal Register, October 30, 2026 notice on peptide compounding
- HHS Opens the Door to Compounding Certain Unapproved Peptides (Morgan Lewis)
- Peptides at a Crossroads (Holland & Knight)
- The Amino-zing World of Peptide Regulation (ArentFox Schiff)
- Alabama Board of Medical Examiners official notice
- Mississippi joint statement on non-FDA-approved peptides
- Public Citizen testimony to FDA, July 2026
- USADA 2026 Clean Sport Handbook
